Intact drugs with splrocyclopropylhexadlenone moieties can be regenerated from the covalent DNA adducts Induced by antitumor antibiotics duocarmycin (DUM) A, SA and some DUMA analogues In neutral aqueous solution. We detected the reversible nature of DUMs by determination of the antimicrobial activity and cytotoxiclty of DUM-DNA adducts. All of the adducts selectively Inhibited the growth of a sensitive strain of Bacillus but not that of the wild type strain, a property of parent DUM and its analogues. Most of the DNA adducts were also cytotoxic to HeLa S3. These results suggested that active drugs can be released from their covalent DNA adducts under these biological assay conditions. Regeneration of intact drugs was quantitatively analyzed by HPLC and the amount of free drug released from DNA adducts revealed that the rate and efficiency of this reversal were dependent on structural variables among the drugs. The differences In rates of reversibility were correlated with the biological activity of DUMs. The effect of pH, temperature and salt concentration on the regeneration of drugs from their DNA adducts suggest a catalytic role of double-helical DNA on the reversal pathway.
INTRODUCTION
Several clinically useful antitumor agents are thought to exhibit their antitumor activity through an interaction with DNA. These clinically important DNA-reactive drugs have been classified into three groups on the basis of mode of drug-DNA interaction: 1) intercalating agents typified by adriamycin, 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA), and actinomycin D; 2) DNA-degradative drugs such as bleomycin; 3) alkylating agents exemplified by cis-diamminedichloroplatinum(II) (cis-DDP) and mitomycin C. However, it has not been clear how these agents show antitumor activity and why some of the DNAreactive compounds, which produce lesions in DNA in vitro exhibit only toxicity or carcinogenicity. In the 1980s, evidence was accumulated to indicate that topoisomerase II is the principal target for intercalating agents such as adriamycin, m-AMSA, and ellipticine (1). Since topoisomerases have been known to be involved in many processes of DNA metabolism including replication and transcription, tumor cells with increased replication and transcription activity are presumably more sensitive than normal cells to treatment by these agents. For these drugs, high levels of the enzyme in proliferating cells and low levels in quiescent cells appear to explain the selectivity of proliferative tumor cells to the cytotoxic effects (1) .
Alkylating agents were thought to be acting through a mechanism initiated with monofunctional or bifunctional covalent alkylation of DNA. But recently there have been reports which presented evidence for the reversibility of covalent reaction between DNA and alkylating drugs, including mitomycin C (2), cis-platinum compounds (3) , and analogues of CC-1065 (5). Tomasz et al. reported that the cross-links of mitomycin C with oligodeoxynucleotides are removed by reducing agents in neutral pH at room temperature, and might generate unidentified degradation products. They mentioned that this reversibility of mitomycin C cross-Unking may operate in a reductive cellular environment. cis-DDP, being widely used in clinical cancer chemotherapy, is thought to be acting via covalent alkylation at N7 of guanine residues in DNA. Gaucheron et al. has shown that the adduct, produced by reaction of cis-[Pt(NH3)2(N7-Nmethyl-2-diazapyrenium)Cl] 2+ (cisPt-MDAP) with oligonucleotide, is kinetically stable within single-stranded DNA but labile within double-stranded DNA. They proposed that the secondary structure of DNA, the double helix, acts as a catalyst in the release of drug from cisPt-MDAP-DNA adduct. The findings reported in 1992 by Warpehoski et al. have renewed interest in the reversibility of DNA-alkylation of antitumor agents. They revealed that DNA-alkylating reaction of adozelesin (an analogue of the antitumor antibiotic CC-1065 with improved antitumor activity), but not of CC-1065 itself, are reversible.
It is considered from these reports that DNA alkylations resulting from antitumor agent interactions can be reversed in solution. If higher reversibility was attained in normal cells than in tumor cells, these alkylating agents would be selectively cytotoxic to tumor cells. Thus reversibility of DNA-drug covalent adducts might be one of the important features of antitumor alkylating agents for acting selectively against tumor cells. To gain a better understanding of the link between antitumor activity and the reversibility of DNA adducts with alkylating agents, we studied here the reversibility of duocarmycins-DNA adducts. A new class of antitumor antibiotics produced by Streptomyces sp., including duocarmycin (DUM) A (6, 7, 8) , B, (9), Bj (9), Ci (8), C 2 (7, 8) , and SA (10, 11, 12) possess potent cytotoxicity. DUMA, Cl, and C2 have been reported to derive their cytotoxicity through a sequence-selective minor groove alkylation at N3 adenine in double stranded DNA (13) (14) (15) (16) (17) (18) . Here we report that the DNA-alkylaring reaction of DUMA, DUMSA and some DUMA analogues (Fig. 1 ) is reversible; drugs can be released from DUM-DNA adducts undergoing a retrohomologous Micheal reaction (5) to form the initial cyclopropylpyrroloindole (Scheme I). We also found that the rate and efficiency of this reversal pathway was affected by structural variables, particularly in the A-ring of the cyclopropylpyrroloindole subunit, presumably explaining the difference in biological effects of these drugs. The effect of pH, temperature and salt concentration on the release of DUMs from their DNA adducts suggests a role for doublehelical DNA in the reversibility.
M10A, wave length: 370nm, column: unisil 5Cig-250A, elution buffer: 40 or 50% CH 3 CN/50 mM potassium phosphate buffer (KPB), pH5.9, flow rate: lmlAnin). Preparation and characterization of DUM -DNA adducts were carried out as follows. DUMs (78/tM) were incubated with calf thymus DNA (1.6mM base pair (bp)) in 10% N.N-dimethylformamide (DMF) lOmM KPB for 24 hours. In these conditions more than 95% of DUMSA was bound to calf thymus DNA as verified by HPLC. Reaction mixtures were extracted with 1:1 phenol-chloroform, ethylacetate, and 1-butanol followed by ethanol precipitation of the DNA. Ultraviolet (UV) and circular dichroism (CD) spectra of prepared DNA adducts were determined and the amount of drug covalently bound to DNA was estimated by UV absorption at 33Onm. The stock solutions of DNA adducts were prepared in lOmM KPB containing 0.25mM covalent drug adducts on calf thymus DNA (about one molecule per 20bp).
Antimicrobial activity against a sensitive strain of Bacillus subtiUs (DR assay) (19)
Melted agar medium prewarmed to 60°C was inoculated with spore suspensions of wild type strain of Bacillus subtiUs at 10 3 spores/ml and a sensitive strain at 10 6 spores/ml, and was poured into plates on a level surface. After solidification, paper disks impregnated with samples containing 6/tl of DUM-DNA adduct stock solution diluted with 34/xl of 0.5M KPB were applied to the agar plates. The plates were then incubated at 37°C for 12 hours. From the diameter of satellite zones formed around the test disks, the amount of drug regenerated from its DNA adduct was estimated.
Cytotoxic activity (20) HeLa S 3 cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, penicillin (100 units/ml) and streptomycin (0.1 mg/ml). For determination of cytotoxic activity of drugs or DNA adducts, HeLa S3 cells were preincubated for 24 h at 37° C in 96 well dishes and then treated with different dilutions of drugs or DNA adducts for one hour. After washing with phosphate-buffered saline (PBS), the cells were cultured in fresh medium for 3 days. Thereafter the concentration of drugs required for 50% inhibition of cell growth was determined by Giemsa staining.
Effect of reaction or structural variables on the release of drug from DUM-DNA adducts in organic/aqueous solvent mixtures 50 /J of DUM -DNA adduct stock solution (250/tM drug adduct) was diluted with 450/J of 0.3M KPB. 1-butanol (600/xl) was introduced and the mixture was stirred. The amount of released drug in the 1-butanol phase was determined by HPLC analysis (370nm) at intervals. Variations in pH, salt concentration, temperature, and drug structure were examined as described in the results section.
MATERIALS AND METHODS
Preparation of calf thymus DNA-DUM adducts DUMSA and DUMA were isolated (6, 10) and 1, 2 and 3 were synthetically derived from DUMB2 in our laboratories. Calf thymus DNA, poly(dAdT)poly(dAdT), and poly(dGdC)-poly(dGdC) were purchased from Sigma. The reaction between DUM and DNA was monitered by reverse phase HPLC analysis (detector: shimadzu photodiode array UV-VIS detector SPD
RESULTS

Preparation and characterization of calf thymus DNA-DUM covalent adducts
The progress of the reaction between drug and DNA at a molecular ratio of drug/DNA bp of 1/20 was analyzed with reverse phase HPLC. The time course of reaction of DUMSA with DNA in 10% DMF/lOmM KPB (pH7) at 37°C is shown in Fig. 2 . Solvolysis of DUMSA, which we can observe as the gradual loss of residual drug, was very slow in the absence of DNA, or in the presence of heat denatured calf thymus DNA or poly(dGdC)poly(dGdQ. On the other hand, the decrease in DUMSA was rapid in the presence of calf thymus DNA or poly(dAdT)poly(dAdT) and no solvolysis product, which appeared in the absence of DNA, was detected in this reaction. These results show the selective binding of DUMSA to AT rich regions of double stranded DNA. After incubation for 24 hours, a nearly quantitative amount of DUMSA (> 95 %) was consumed for DNA alkylation in the presence of calf thymus DNA. DUMA and synthetic analogues, 1,2 and 3, bearing a spirocyclopropylhexadienone moiety as a common pharamacophore for DNA alkylation, also alkylated calf thymus DNA to produce covalent adducts and these agents were different in their rates of DNAalkylation (18) . After complete consumption of drug during 24 hours, drug-modified DNAs were further purified to remove the trace amounts of unbound drug (see Materials and Methods). These DNA adducts were characterized by UV and CD spectra (data not shown) and a thermally-induced depurination reaction which produces DUM-base adducts (13, 17, 18) .
Antimicrobial and cytotoxk activity of DUM-DNA covalent adducts
To investigate the reversibility of DUMSA-DNA covalent binding, antimicrobial activity of the DUMSA-DNA adducts was determined on the agar plate inoculated with both wild type and a sensitive strain of Bacillus subtilis which is deficient in enzyme for recombination (rec~). (Fig. 3 ) DUMSA inhibited growth of the rec~ mutant strain selectively, forming satellite zones around the paper disks impregnated with drug. We have discovered that DUMSA-calf thymus DNA adduct solution in 0.5M KPB also inhibited the rec" mutant strain. A remarkable promotion of the antimicrobial activity of DUMSA-DNA adduct was observed by raising the pH of the solutions from 6 to 8 (Fig.  3A , Diameter of satelite zone was 12mm at pH6 and 18mm at pH8), while the activity was decreased at low buffer concentration (Diameter of satelite zone of DNA adduct diluted in 0.23M KPB, pH8, was 9mm), although the activity of the free drug was independent of pH or concentration of all buffers used in this study. Antimicrobial activity was suppressed in the presence of competitive free calf thymus DNA and poly(dAdT)poly(dAdT) but not in the presence of poly(dGdC)poly(dGdC) nor heat denatured calf thymus DNA (Fig. 3B, Q . The DUMSA-N3 adenine adduct, which was obtained by thermally induced reaction (18), did not exhibit antimicrobial activity under these conditions. These results indicate that intact DUMSA, bearing the spirccyclopropylhexadienone moiety which is required for exhibiting its biological effect, can be released from its covalent DNA adduct and inhibit the growth of a rec ~ mutant bacterial strain in the absence of competitive DNA. DNA adducts of DUMA and its analogues, 1, 2 and 3 also exhibited antimicrobial activity against the rec" mutant strain in a pH-dependent manner. We estimated the amount of released drugs from the diameter of satelite zone surrounding the disc, which is known to be proportional to the amount of free drug. As shown in Fig. 4 , the amount of drugs released from their DNA adducts, alternatively, the rate of cyclopropane formation from DNA adducts depended on the structural variables of the drugs.
The DNA adducts of DUMSA, 1, 2 and 3 showed potent cytotoxicity against HeLa S3 (Table I ). The cytotoxicity of DNA adducts were 1/7.5 to 1/115 of the corresponding free drugs. The ratio of ICso's of adducts and free drugs indicates a correlation between cytotoxicity and the rate of regeneration of intact drugs from their DNA adducts, which is essentially comparable to the data obtained by antimicrobial assay and by DUMA DUMSA HPLC analysis of free drug formation using l-butanol extraction (see below).
HPLC analysis of DUMSA released from DNA-DUMSA covalent adducts and the effect of reaction variables on the release of DUMSA To observe the regeneration of DUMSA we tried continuous extraction with l-butanol of the product which is generated from DUMSA-DNA adducts in buffered solution (pH8). The product extracted into l-butanol phase from the solution of DUMSA-DNA adduct had the same retention time as intact DUMSA in HPLC (unisil 5C 18 -250A, 50% CH 3 CN/50 mM KPB, pH5.9, 7.4min), and the UV spectrum of the product was identical to that of DUMSA, with maxima at 230nm, 320nm and 370nm (10) . This showed that intact drug was released from DUMSA-DNA covalent adduct extracted from buffer solution into organic phase (No free drug was detected in the buffer layer). The amount of free drug in the l-butanol phase was determined by HPLC. The time course of the release of DUMSA from DNA -DUMSA adducts in solution is shown in Fig. 5 . More than 50% of DUMSA was released after incubation for 4 days at 37° C in l-butanol/270mM phosphate buffer (pH8) solvent mixture. At 60°C, 97% of DUMSA was regenerated from the adduct within 1 day (Fig. 5B) . The rate of this cyclopropane formation was decreased as the pH of the buffer was decreased (Fig. 5C) , which is consistent with data obtained from the antimicrobial assay.
Effect of DNA structure on the release of DUMSA from its DNA adducts Dilution of DUMSA-DNA adducts with 1M glycine-NaOH buffer also resulted in the inhibition of growth of the recB .subtilis strain. Antimicrobial activity was increased as the pH of the buffer was raised from 8.5 to 11 (Diameter of satelite zone was 14mm at pH8.5 and 21.5mm at pHll) and decreased at above pHl 1 (Diameter of satelite zone was 17mm at pH12 and 10mm at pH12.8). The regeneration of drug from DNA adduct (Fig. 5B) was accelerated by raising the temperature from 37°C to 60°C. However depurination of N3 alkylated adenine prevails and generate DUMSA-N3 adenine adduct mainly (95% determined by HPLC) in lOmM phosphate buffer (pH7) at 100°C for 20 min. These results suggest that active drug can be released from double stranded DNA but not from heat or alkaline denatured DNA. Furthermore the addition of NaCl (1.5 or 3.0M) suppressed the reversal pathway (Fig. 5D) suggesting that the reversibility of DUM-DNA adduct depends on the conformation of double stranded DNA.
Relation between the structure of drugs and the reversibility of DNA-drug interactions Regeneration of the cyclopropyl group of DUMA analogues 1, 2 and 3 from their DNA adducts could also be detected by HPLC analysis of free drug extracted into 1-butanol phase (Fig. 6) . Almost quantitative amounts of 2 (95 %) were released from DNA adducts during 6 days incubation at 37°C. Under this condition DUMSA gave 80% recovery, and 3 gave a higher yield (40%) than 1 (30%). However we could not detect released DUMA nor its solvolytic compounds from DNA-DUMA adducts at 37°C. A small amount of DUMA (< 10%) was released after 1 hr incubation at 80°C, indicating that the rate of regeneration of DUMA is very slow compared to other duocarmycin homologues. Thus, it seems that the order of reversibility of DNA-drug interactions with duocarmycin homologues is as follows : 2 > DUMSA > 3 > 1 > > DUMA.
DISCUSSION
The present study has provided evidence that intact active DUMs with a spirocyclopropylhexadienone moiety can be released from DUM-DNA covalent adducts (scheme I). Free drugs released from solutions of their DNA adducts inhibited the growth of a rec~ mutant strain of Bacillus subtilis in the absence of competitive DNA. In the presence of double stranded DNA or poly(dAdT)poly(dAdT), released drugs could alky late available sites on these DNAs. Thus free drugs trapped by competitive DNA were unavailable for antimicrobial activity. The alkylation reversal pathway was accelerated by raising the temperature and pH of the buffer and by increasing the buffer concentration. These results are consistent with the report on CC-1065 analogues (5). The reverse alkylation of CC-1065 has been formally described as 'a retrohomologous Micheal reaction' by Warpehoski et al. Since also DUMs alkylate at the N3 adenine position of DNA (18) , release of intact DUMs from their covalent DNA adducts, that is, regeneration of the cyclopropylpyrroloindole subunits seems to be occur via a retrohomologous Micheal reaction (5) .
Interestingly, the structural variables in the A-ring of the left hand segment (DUMA, DUMSA, 1, and 2) affected the regeneration of intact drug. From a previous study on DNA alkylation of DUMs we concluded that electrophilicity of the cyclopropane subunit is dependent mainly on the A-ring structure of the left hand segment of DUMs. Differences in electrophilicity affect rates of solvolysis and selectivity for N3 adenine alkylation (18) . And now we have shown that A-ring structure affects the reversal alkylation pathway. Release of DUMA (containing aZter^-cyclopropylpyrroloindole unit on left hand segment) from its DNA adduct was very slow compared to the cyclopropylpyrroloindole unit of other DUMs described in this study. C2 and C3 substituent of cyclopropylpyrroloindole unit (Fig. 1, X and Y) also influenced the rate and efficiency of cyclopropylpyrroloindole formation, yielding 80% of DUMSA, 36% of 1, and 95% of 2 in 6 days (Fig. 6) . Furthermore the structure of the right hand segment also affected the reversibility of DUM (yielding 47% of 3 and 36% of 1 in 6 days), presumably, due to the difference in hydrophobic interaction with the minor groove of DNA.
Gaucheron et al. proposed that the DNA double helix acts as a catalyst in the lability of platinated DNA (3, 4) . In a similar manner, double helical B form DNA seems to be required for the release of intact DUM from their DNA adducts for the following reasons. 1) Depurination of N3 alkylated adenine prevails at temperatures above 90°C and the regeneration of active drug is decreased above pHl 1, at which condition DNA is denatured.
2) The addition of NaCl up to 3M suppressed the release of DUMSA; under this condition, a different conformation of DUMSA-modified DNA was confirmed by CD spectrum (data not shown).
DNA alkylating agents such as mitomycin C and cis-DDP have been shown to be important drugs for clinical treatment of cancer. Although it is generally accepted that some of these agents are acting through a mechanism initiated with covalent alkylation of DNA, the mechanism whereby these alkylating agents exert antitumor activity remains unknown; some DNA alkylating compounds, such as aflatoxin Bl, monocrotaline, and ptaquiloside exhibit toxicity or carcinogenicity rather than antitumor activity. On the basis of the results described here and those reported for mitomycin C (2), cisPt-MDAP (3, 4) , and CC-1065 analogues (5), we would like to suggest that reversible reactions might play a role in the selective inhibition of tumor cells by antitumor alkylating agents. From this standpoint, it is interesting that DUMA was less active in murine and human tumor xenograft models than DUMSA, 1 and 3 in vivo (unpublished data), which correlates with the difference in chemical reversibility of DNA-drug adducts.
